

PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicant(s):</b>	Mohamad A. Morsey, et al.	<b>Examiner:</b>	Unassigned
<b>Serial No.:</b>	Unassigned	<b>Art Unit:</b>	Unassigned
<b>Filed:</b>	Herewith	<b>Docket:</b>	16499Z (PC10761B)
<b>For:</b>	ANTI-IGE VACCINES	<b>Dated:</b>	January 5, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the references listed on the attached Form PTO-1449, be made of record in the above-identified case.

---


**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

**"Express Mail" Mailing Label Number:** EV 267607464 US

**Date of Deposit:** January 5, 2004

I hereby certify that this Correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 5, 2004




Peter I. Bernstein

Pursuant to 37 C.F.R. §1.98(d), copies of the references listed on the attached Form PTO-1449 are not provided, as references were previously submitted to the Examiner and references were cited by the Examiner in connection with parent case, U.S. Serial Number: 09/938,700, filed August 24, 2001.

Consideration of this Information Disclosure Statement is respectfully requested.

Respectfully submitted,



Peter I. Bernstein  
Registration No. 43,497

Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

PIB:dg



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC10761A							SERIAL NO. 09/938,700		
		APPLICANT MORSEY, ET AL.									
		FILING DATE AUGUST 24, 2001							GROUP 1646		

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4	9	8	0	2	8	6					
		5	4	3	6	1	4	6	7/95	Shenk, et al.			
		5	6	0	1	8	2	1	2/97	Stanworth, et al.			
		5	6	5	3	9	8	0	8/97	Hellman			

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		0	2	6	3	6	5	5					YES	NO
		9	2	0	6	1	8	0	4/88	EP				
		9	2	2	0	3	1	6	4/92	PCT				
		9	2	2	2	6	3	5	11/92	PCT				
		9	2	2	2	6	3	5	12/92	PCT				
		9	3	1	4	1	8	8	7/93	PCT				
		9	3	2	0	2	2	1	7/93	PCT				
		9	4	0	8	5	9	8	4/94	PCT				
		9	4	1	2	6	4	9	6/94	PCT				
		9	7	3	1	9	4	8	9/97	PCT				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1.		Burt, et al.; Eur. J. Immunol.; Inhibition of Binding of Rat IgE to rat mast Cells by Synthetic IgE Peptides; Vol. 17:437-440 (1987).
2.		Helm, et al.; Nature; The Mast Cell Binding Site on Human Immunoglobulin E; Vol. 331: 180-183 (1988).
3.		Helm, et al.; Proc. Natl. Acad. Sci.; Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by a recombinant human ε-chain fragment of 76 amino acids; Vol. 86, p. 9465-9469 (1989).
4.		Vercelli, et al.; Nature; The B-Cell binding site on human immunoglobulin E; Vol. 338:649-651 (1989).
5.		Nio, et al.; FEBS Letter; Inhibition of passive sensitization of human peripheral basophils by synthetic human immunoglobulin E peptide fragments; 319:225-228 (1993).
6.		Nio, et al.; FEBS Letter; Inhibition of passive cutaneous anaphylaxis by synthetic human immunoglobulin E peptide fragments; Vol. 314, No. 3, p 229-231 (1992).
7.		Basu, et al.; The J. of Biological Chemistry; Purification and Characterization of Human Recombinant IgE-Fc Fragments that Bind to the Human High Affinity IgE Receptor; Vol. 268, No. 18, p. 13118-13127 (1993).

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10761A	SERIAL NO. 09/938,700
			APPLICANT MORSEY, ET AL.	
			FILING DATE AUGUST 24, 2001	GROUP
8.			Vangelista, et al.; The J. of Clinical Investigation; The Immunoglobulin-like modules Cε3 and α2 are the minimal units necessary for human IgE-FcεRI interaction; Vol. 103: p. 1571-1578 (1999).	
9.			Robertson, et al.; Molecular Immunology; IgE Structure-Function relationships Defined by Sequence Directed Antibodies Induced by Synthetic Peptides; Vol. 25, No. 2, p. 103-113 (1988).	
10.			Schwarzbaum, et al.; European J. of Immunology; Mapping of Murine IgE Epitopes Involved in IgE-Fc <sub>ε</sub> Receptor Interactions; 19:1015-1023 (1989).	
11.			Weetall, et al.; The J. of Immunology; Mapping the Site of Interaction between Murine IgE and its High Affinity Receptor with Chimeric Ig <sup>1</sup> ; 145:3849-3854 (1990).	
12.			Presta, et al.; The J. of Biological Chemistry; The Binding Site on Human Immunoglobulin E for Its High Affinity Receptor; 269:26368-26373 (1994).	
13.			Nissim, et al.; The J. of Immunology; Fine Specificity of the IgE Interaction with the Low and High Affinity Fc Receptor <sup>1</sup> ; 150:1365-1374 (1993).	
14.			Del Prado, et al.; Molecular Immunology; Monoclonal Antibodies Against Human IgE, Identification of an Epitope Sharing Properties with the High-Affinity Receptor Binding Site; 28:839-844 (1991).	
15.			Keegan, et al.; Molecular Immunology; Characterization of New Rat Anti-Mouse IgE Monoclonals and their use along with Chimeric IgE to Further Define the Site that Interacts with Fc <sub>ε</sub> RII and R <sub>c</sub> RI; 28:1149-1154 (1991).	
16.			Hook, et al.; Molecular Immunology; Monoclonal Antibodies Defining Epitopes on Human IgE; 28:631-639 (1991).	
17.			Takemoto, et al.; Microbiol. Immunology; Anti-Human IgE Monoclonal Antibodies Recognizing Epitopes Related to the Binding Sites of High and Low Affinity IgE Receptors; 38(1), p 63-71 (1994).	
18.			Baniyashi, et al.; Molecular Immunology; Anti-IgE Monoclonal Antibodies Directed at the Fc <sub>ε</sub> Receptor Binding Site; 25:705-711 (1988).	
19.			Chang, T.W.; Nature; The Pharmacological Basis of Anti-IgE Therapy; 157-162 (2000).	
20.			Presta, et al.; The J. of Immunology; Humanization of an Antibody Directed Against IgE; 151:2623-2632 (1993).	
21.			Stadler, et al.; Int. Arch Allergy Immunol.; Biological Activities of Anti-IgE Antibodies; 102:121-126.	
22.			Rudolf, et al.; J. of Immunology; Epitope-Specific Antibody Response to IgE by Mimotope Immunization <sup>1</sup> ; 160:3515-3321.	
23.			Xiu-min Li, et al.; J. Allergy Clin. Immunology; A Murine Model of IgE-mediated cow's milk hypersensitivity; 103:206-214 (1999).	
24.			Xui-Min Li, et al.; J. Allergy Clin. Immunology; Murine Model of Atopic Dermatitis Associated with Food Hypersensitivity; 107:693-702 (2001).	
25.			Ermel, et al.; Laboratory Animal Science; The Atopic Dog: A Model for Food Allergy; Vol. 47, No. 1, p. 40-48 (1997).	
26.			McDermott, et al.; Molecular Immunology; Identification, cloning, and characterization of a major cat flea salivary allergen (Cte f 1) 37:361-375 (2000).	
27.			Underwood, et al.; Immunology; IgE Production, Antigen-induced airway inflammation and Airway Hyperreactivity in the Brown Norway rat: the Effects of Ricin; 85:256-261 (1995).	
28.			Underwood, et al.; Int. Arch Allergy Immunology; Ricin Increases IgE Levels and Airway Inflammation but Not Hyperresponsiveness in the Rat; 107:119-121 (1995).	
29.			Diaz-Sanchez, et al.; Immunology; Generation of a long-lived IgE Response in High and Low Responder Strains of rat by co-administration of Ricin and Antigen; Immunology; 72:297-303 (1991).	

**BEST AVAILABLE COPY**

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10761A	SERIAL NO. 09/938,700
			APPLICANT MORSEY, ET AL.	
			FILING DATE AUGUST 24, 2001	GROUP
30.			Noble, et al.; Immunology; Elimination of IgE Regulatory Rat CD8 <sup>+</sup> T Cells in Vivo Increases the Co-ordinate Expression of Th2 cytokines IL-4, IL-5 and IL-10; 80:326-329 (1993).	
31.			Diaz-Sanchez, et al.; Immunology; Ricin Enhances IgE responses by Inhibiting a Subpopulation of Early-Activated IgE Regulatory CD8 <sup>+</sup> T Cells; 78:226-236 (1993).	
32.			Karin, et al.; Proc. Natl. Acad. Sci.; Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes; Vol. 87, p. 2264-2268 (1990).	
33.			Karin, et al.; Proc. Natl. Acad. Sci.; Applications and Statistics for Multiple High-scoring Segments in Molecular Sequences; Vol. 90, p. 5873-5877 (1993).	
34.			Pearson, et al.; Proc. Natl. Acad. Sci.; Improved Tools for Biological Sequence Comparison; Vol. 85, p. 24444-2448 (1988).	
35.			Benoist, et al.; Nature; In Vivo Sequence Requirements of the SV40 Early Promoter Region; 290:304-310 (1981).	
36.			Yamamoto, et al.; Cell; Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus; Vol. 22, p. 787-797 (1980).	
37.			Wagner, et al.; Proc. Natl. Acad. Sci.; Nucleotide Sequence of the Thymidine Kinase Gene of Herpes Simplex Virus Type 1; Vol. 78, No. 3, p. 1441-1445 (1981).	
38.			Brinster, et al.; Nature; Regulation of Metallothionein-thymidine Kinase Fusion plasmids injected into Mouse Eggs; 296:39-42 (1982).	
39.			Villa-Komaroff, et al.; Proc. Natl. Acad. Sci.; A Bacterial Clone Synthesizing Proinsulin; 75:3727-3731 (1978).	
40.			DeBoer, et al.; Proc. Natl. Acad. Sci.; The tac promoter: A functional hybrid derived from the trp and lac promoters; Vol. 80, p. 21-25 (1983).	
41.			Gilbert, et al.; Scientific American; Useful Proteins from Recombinant Bacteria; 242:74-94 (1980).	
42.			Torelli, et al.; Comput Appl. Biosci.; Advance and Adam: Two algorithms for the analysis of global similarity between homologous informational sequences; Vol. 10, No. 1, p. 3-5 (1994).	
43.			Herrera-Estrella, et al.; Nucl. Acids Res.; Expression of chimaeric genes transferred into plant cells using a Ti-plasmid-derived vector; 303:209-213.	
44.			Gardner, et al.; Nucl. Acids Res.; Abstract; Vol. 9, No. 12, p. 2871-2888 (1981).	
45.			Herrera-Estrella, et al.; Nature; 310:115-120.	
46.			Swift, et al.; Cell; Tissue-Specific Expression of the Rat Pancreatic Elastase I Gene in Transgenic Mice; 38:639-646 (1984).	
47.			Ormitz, et al.; Cold Spring Harbor Symp. Quant. Biol.; Elastase I Promoter Directs Expression of Human Growth Hormone and SV40 T Antigen Genes to Pancreatic Acinar Cells in Transgenic Mice; 50:399-409 (1986).	
48.			MacDonald, R.J.; Hepatology; Expression of the Pancreatic Elastase I Gene in Transgenic Mice; 7:425-515 (1987).	
49.			Hanahan, D.; Nature; Heritable formation of pancreatic $\beta$ -cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes; 315:115-122 (1985).	
50.			Grosschedl, et al.; Cell; Introduction of a $\mu$ Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody; 38:647-658 (1984).	
51.			Adams, et al.; Nature; The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice; 318:533-538 (1985).	

**BEST AVAILABLE COPY**

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10761A	SERIAL NO. 09/938,700
			APPLICANT MORSEY, ET AL.	
			FILING DATE AUGUST 24, 2001	
52.			Alexander, et al.; Molecular and Cellular Biology; Expression of the c-myc Oncogene under control of an immunoglobulin enhancer in E $\mu$ -myc Transgenic Mice; Vol. 7, No. 4, p. 1436-1444 (1987).	GROUP
53.			Pattengale, et al.; Cell; Consequences of Widespread Deregulation of the c-myc Gene in Transgenic Mice: Multiple Neoplasms and Normal Development; Vol. 45, p. 485-495 (1986).	
54.			Leder, et al.; Cell; Consequences of Widespread Deregulation of the c-myc gene in transgenic mice: Multiple Neoplasms and Normal Development; 45:485-495 (1986).	
55.			Pinkert, et al.; Genes and Development; An albumin enhancer located 10-kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice; 1:268-276 (1987).	
56.			Krumlauf, et al.; Molecular and Cellular Biology; Developmental Regulation of $\alpha$ -Fetoprotein Genes in Transgenic Mice; Vol. 5, No. 7, p. 1639-1648 (1985).	
57.			Hammer, et al.; Science; Diversity of Alpha-Fetoprotein Gene Expression in Mice Is Generated by a Combination of Separate Enhancer Elements; 235:53-58 (1987).	
58.			Kelsey, et al.; Genes & Development; Species- and tissue-specific expression of human $\alpha_1$ -antitrypsin in transgenic mice; 1:161-171 (1987).	
59.			Magram, et al.; Nature; Developmental regulation of a cloned adult $\beta$ -globin gene in transgenic mice; 315:338-340 (1985).	
60.			Kollias, et al.; Cell; Regulated Expression of Human $\gamma$ -Y-, $\beta$ -, and Hybrid $\gamma\beta$ -Globin Genes in Transgenic Mice: Manipulation of the Developmental Expression Patterns; Vol. 46, 89-94 (1986).	
61.			Readhead, et al.; Cell; Expression of a Myelin Basic Protein Gene in Transgenic Shiverer Mice: Correction of the Dysmyelinating Phenotype; Vol. 48, 703-712 (1987).	
62.			Shani, M.; Nature; Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice; Vol. 314:283-286 (1985).	
63.			Reecy, et al.; Animal Biotechnology; Multiple Regions of the Porcine $\alpha$ -Skeletal Actin Gene Modulate Muscle-specific Expression in Cell Culture and Directly Injected Skeletal Muscle; 9(2), p. 101-120 (1998).	
64.			Mason, et al.; Science; The Hypogonadal Mouse: Reproductive Functions Restored by Gene Therapy; Vol. 234:1273-1378 (1986).	
65.			Wigler, et al.; Cell; Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells; Vol. 11 p. 223-232 (1977).	
66.			Szybalska, et al.; Proc. Natl., Acad Sci.; Genetic of Human Cell Lines, IV.; 48:2026-2034 (1962).	
67.			Lowy, et al.; Cell; Isolation of Transforming DNA: Cloning the Hamster apt Gene; Vol. 22, p. 817-823 (1980).	
68.			Wigler, et al.; Proc. Nalt. Acad. Sci.; Transformation of mammalian cells with an amplifiable dominant-acting gene; Vol. 77, No. 6, p. 3567-3570 (1980).	
69.			O'Hare, et al.; Proc. Natl. Acad. Sci.; Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase; 78:1527 (1981).	
70.			Mulligan, et al.; Proc. Natl. Acad. Sci.; Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase; Vol. 78, No. 4, p. 2072-2076 (1981).	
71.			Colbere-Garapin, et al.; J. Mol. Biol.; A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells; 150:1-14 (1981).	
72.			Santerre, et al.; Gene; Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells; 30:147-156 (1984).	
73.			Goldspiel, et al.; Clinical Pharmacy; Clinical Frontiers; Vol. 12, p. 488-505 (1993).	

BEST AVAILABLE COPY

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10761A	SERIAL NO. 09/938,700
			APPLICANT MORSEY, ET AL.	
			FILING DATE AUGUST 24, 2001	GROUP
74.			Wu, et al.; Biotherapy; Delivery systems for gene therapy; 3:87-95 (1991).	
75.			Tolstoshev; Ann. Rev. Pharmacol. Toxicol.; Gene Therapy, Concepts, Current Trials and Future Directions; 32:573-596 (1993).	
76.			Mulligan, R.; Science; The Basic Science of Gene Therapy; 260:926-932 (1993).	
77.			Morgan and Anderson, et al.; Ann. Rev. Biochem.; Human Gene Therapy; 62:191-217 (1993).	
78.			Robinson, C.; Tibtech; Gene Therapy – proceeding from laboratory to clinic; 11(5):155-215 (1993).	
79.			Koller, et al.; Proc. Natl. Acad. Sci.; Inactivating the $\beta_2$ -microglobulin locus in mouse embryonic stem cells by homologous recombination; Vol. 86, p. 8932-8935 (1989).	
80.			Koller, et al.; Proc. Natl. Acad. Sci.; Inactivating the $\beta_2$ -microglobulin locus in mouse embryonic stem cells by homologous recombination; Vol. 86, p. 8932-8935 (1989).	
81.			Zijlstra, et al.; Nature; Germ-line transmission of a disrupted $\beta_2$ -microglobulin gene produced by homologous recombination in embryonic stem cells; 342:435-438 (1989).	
82.			Wu, et al.; J. Biol. Chem.; Recetor-mediated in Vetro Gene Transformation by a Soluble DNA Carrier System; Vol. 262, No. 10, p. 4429-4432 (1987).	
83.			Miller, et al.; Meth. Enzymol.; Use of Retroviral Vectors for Gene Transfer and Expression; 217:581-599.	
84.			Clowes, et al.; J. Clin. Invest; Long-Term Biological Response of Injured Rat Carotid Artery Seeded with Smooth Muscle Cells Expressing Retrovirally Introduced Human Genes; 93:644-651 (1994).	
85.			Kiem, et al.; Blood; Retrovirus-Mediated Gene Transduction Into Canine Peripheral Blood Repopulating Cells; 83:1467-1473 (1994).	
86.			Salmons, et al.; Human Gene Therapy; Targeting of Retroviral Vectors for Gene Therapy; 4:129-141 (1993).	
87.			Grossman, et al.; Current Opinion in Genetics and Devel.; Retroviruses: delivery vehicle to the liver; 3:110-114 (1993).	
88.			Bout, et al.; Human Gene Therapy; Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium; 5:3-10 (1994).	
89.			Rosenfeld, et al.; Science; Adenovirus-Mediated Transfer of a Recombinant $\alpha$ -1-Antitrypsin Gene to the Lung Epithelium in Vivo; 252:431-434 (1991).	
90.			Rosenfeld, et al.; Cell; In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium; 68:143-155 (1992).	
91.			Mastrangeli, et al.; J. Clin. Invest.; Diversity of Airway Epithelial Cell Targets for the Vivo Recombinant Adenovirus-mediated Gene Transfer; 91:225-234 (1993).	
92.			Wang, et al.; Gene Therapy; A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-regio deletions; 2:775-783 (1995).	
93.			Walsh, et al.; Proc. Soc. Exp. Biol. Med.; Gene Therapy for Human Hemoglobinopathies; 204:289-300.	
94.			Loeffler, et al; Methods in Enzymology; 217:599-618 (1993).	
95.			Cotten, et al.; Methods in Enzymology; Receptor-Mediated Transport of DNA into Eukaryotic Cells; Vol. 217, p. 618-644 (1993).	
96.			Cline, M.; Pharmac. Ther.; Perspectives for Gene Therapy; 29:69-92.	
97.			Stemple, et al.; Cell; Isolation of a Stem Cell for Neurons and Glia from the Mammalian Neural Crest; 71:973-985 (1992).	

**BEST AVAILABLE COPY**

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC10761A	SERIAL NO. 09/938,700
		APPLICANT MORSEY, ET AL.	
		FILING DATE AUGUST 24, 2001	GROUP
98.		Rheinwald, J.; Methods in Cell Biology; Serial Cultivation of Normal Human Epidermal Keratinocytes; 21a:229-2554.	
99.		Pittelkow, et al.; Mayo Clinic Proc.; New Techniques for the In Vitro Culture of Human Skin Keratinocytes and Perspectives on Their Use for Grafting of Patients with Extensive Burns; 61:771-777 (1986).	
100.		Langer, R.; Science; New Methods of Drug Delivery; 249:1527-1533 (1990).	
101.		Treat, et al.; Liposomes in the Therapy of Infectious Diseases and Cancer; Liposome Encapsulated Doxorubicin Preliminary Results of Phase I and Phase II Trials; pp. 353-365 (1989).	
102.		Sefton, M.; CRC Crit Ref. Biomed. Eng.; Implantable Pumps; 14:201-240 (1987).	
103.		Buchwald, et al.; Surgery; Long-Term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis; 88:507-116 (1980).	
104.		Saudek, et al.; New Engl. J. Med.; A preliminary trial of the programmable implantable medication system for insulin delivery; 321:574-579 (1989).	
105.		Levy, et al.; Science; Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate; 228:190-192 (1985).	
106.		During, et al.; Am. Neurological Assoc.; Controlled Release of Dopamine from a polymeric brain implant: In vivo characterization; 25:351-356 (1989).	
107.		Howard, et al.; J. Neurosurg; Intracerebral drug delivery in rats with lesion-induced memory deficits; 71:105-112 (1989).	
108.		Goodson; Medical Applns. of Controlled Release supra Vol. II p. 115-138 (1984).	
109.		Joliot, et al.; Proc. Natl. Acad. Sci.; Antennapedia homeobox peptide regulates neural morphogenesis; 88:1864-1868 (1991).	
110.		Langer, et al.; JMS - Rev. Macromol. Chem. Phys.; Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review; 23:61-126 (1983).	
EXAMINER		DATE CONSIDERED	
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

BEST AVAILABLE COPY